Form 4: Catalyst Pharma CEO's Equity Activity

Catalyst Pharmaceuticals CEO Richard J. Daly reported new equity grants and RSU vesting, alongside shares withheld for taxes.

Summary

• CEO Richard J. Daly acquired 20,006 shares of common stock through the vesting of restricted stock units on November 21, 2025.
• 7,872 shares were withheld by the company to cover applicable withholding taxes related to the RSU vesting.
• Daly was granted 381,948 options to purchase common stock at an exercise price of $22.77 on November 20, 2025, vesting in three equal annual tranches starting November 20, 2026, and expiring November 20, 2032.
• Daly also received a grant of 115,283 Restricted Stock Units on November 20, 2025, vesting in three equal annual tranches starting November 20, 2026.
• Following these transactions, Daly directly beneficially owns 238,928 shares of common stock, 2,546,695 options to purchase common stock, and 2,661,978 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation activities, including significant new equity grants, which are generally positive for aligning management incentives with shareholder value. The tax withholding is a standard, neutral event. No negative operational news is present.

Positives

• Grant of 381,948 stock options and 115,283 Restricted Stock Units indicates continued incentive alignment with shareholder interests.
• Vesting of 20,006 Restricted Stock Units demonstrates the realization of previously granted equity compensation.

Negatives

• Disposal of 7,872 shares for tax withholding reduces direct share ownership, though this is a standard practice for equity compensation.

Future Outlook

The grants of new stock options and restricted stock units indicate a long-term incentive structure for the CEO, aligning future performance with equity vesting schedules extending through 2028 and option expiration in 2032.

Industry Context

This filing reflects standard executive compensation practices within the pharmaceutical industry, where equity grants like stock options and restricted stock units are common tools to incentivize long-term performance and align management interests with shareholders. The specific values and vesting schedules are typical for a CEO of a publicly traded biopharmaceutical company.

Comparison to Industry Standards

• The equity compensation package, including stock options and restricted stock units with multi-year vesting schedules, is consistent with common practices for executive compensation in the U.S. pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar structures to retain and motivate key executives, linking a significant portion of their compensation to company stock performance over several years.
• The exercise price of $22.77 for the options would typically be set at the closing market price on the grant date, a standard industry practice.

Stakeholder Impact

• Shareholders: Alignment of CEO's long-term interests with company performance through equity grants.
• Employees: Standard executive compensation practices may set a precedent or reflect overall company compensation philosophy.

Next Steps

• Future vesting of 381,948 stock options on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of 115,283 Restricted Stock Units on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of 20,006 Restricted Stock Units on November 21, 2026, and November 21, 2027.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for the CEO, including new grants of stock options and restricted stock units, and the vesting of prior awards with associated tax withholding. These transactions are standard practice for executive incentive plans and do not provide new information that would fundamentally alter the investment thesis for Catalyst Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, as the filing neither presents significant positive catalysts nor concerning red flags that would warrant a change in investment position based solely on this report.

Keywords

Catalyst Pharmaceuticals, CPRX, Richard J. Daly, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Equity Compensation, CEO, Director